Docetaxel in Non Small Cell Lung Cancer (NSCLC)
This study has been terminated.
Information provided by:
First received: December 6, 2005
Last updated: March 18, 2008
Last verified: March 2008
- To compare the tumour response rate of combination chemotherapy irinotecan/cisplatin (IC) versus docetaxel/cisplatin (DC) in advanced NSCLC patients who responded to 3 courses of docetaxel/cisplatin.
Secondary Objectives :
- To compare the time to progression after chemotherapy treatment between the IC and DC arms of treatment.
- To compare the toxicity profile of the IC and DC arms of treatment.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Pilot Study of Combination of Irinotecan and Cisplatin in Docetaxel/Cisplatin-Responsive Advanced Non-Small Cell Lung Cancer|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Sanofi:
Contacts and Locations